Aquestive Therapeutics, Inc. AQST Liability related to the sale of future revenue, current
Liability related to the sale of future revenue, current at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept aqst:TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current?
- Aquestive Therapeutics, Inc. (AQST) reported liability related to the sale of future revenue, current of $1M in Q1 2026.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s liability related to the sale of future revenue, current has grown at a -7.2% compound annual growth rate (CAGR), from $1.45M to $1M.
- What does liability related to the sale of future revenue, current mean?
- This represents the current portion of obligations arising from the sale of future revenue streams, often structured as a financing arrangement. It reflects the amount of future cash flows that must be remitted to third parties within the next twelve months. Investors monitor this to assess short-term liquidity pressure and the impact of revenue-sharing agreements on future cash availability.